Arş. Gör. HAKAN TABAN

Yayın Ağı

Makaleler 25

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.

Acta Medica , cilt.56, sa.3, ss.186-198, 2025 (TRDizin)

2. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.

JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus)

3. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)

4. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , cilt.47, sa.3, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

DEMİR M., Guven D., AKTAŞ B. Y., GÜNER G., AKTEPE O. H., TABAN H., et al.

SOUTH ASIAN JOURNAL OF CANCER , cilt.11, ss.287-292, 2022 (ESCI, Scopus)

6. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)

7. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

TABAN H., GÜVEN D. C., Kilickap S.

CUREUS JOURNAL OF MEDICAL SCIENCE , cilt.14, sa.8, 2022 (ESCI)

8. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment

Guven D. C., Taban H., Dizdar O.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.1, ss.203-204, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma

10. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)

11. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

FUTURE ONCOLOGY , cilt.17, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

13. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

Guven D. C., Yildirim H. C., Bilgin E., Aktepe O. H., Taban H., Sahin T. K., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY , cilt.23, sa.8, ss.1630-1636, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

17. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.

TURKISH JOURNAL OF UROLOGY , cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)

18. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

19. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis

Aktas B. Y., Degirmenciler R. F., Durmaz C. D., Taban H., Guven D. C., Guner G., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

21. Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

Efil S. C., Guner G., Guven D. C., Celikten B., Celebiyev E., Taban H., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

22. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)

23. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.

CLINICAL COLORECTAL CANCER , cilt.19, sa.3, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 6

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2. Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., Kilickap S., Turker A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

3. Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days

Aktas B. Y., Guven D. C., Degirmenciler R. F., Taban H., Aktepe O. H., Kertmen N., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

4. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

5. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

6. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler